---
title: "Major Insider Move at Globus Medical Sparks Investor Buzz"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289275487.md"
description: "Globus Medical (GMED) director David Davidar sold 25,000 shares worth $2.019 million on June 9, 2026, sparking investor interest. Despite this insider sale, GMED's stock was supported by strong Q1 results featuring double-digit revenue growth and raised EPS guidance. TipRanks' AI Analyst 'Spark' rates GMED as an Outperform, citing strong fundamentals and reasonable valuation (~18x earnings), though technical weakness and Nevro integration risks remain concerns."
datetime: "2026-06-10T02:08:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289275487.md)
  - [en](https://longbridge.com/en/news/289275487.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289275487.md)
generator: "portal-rs"
---

# Major Insider Move at Globus Medical Sparks Investor Buzz

New insider activity at Globus Medical ( (GMED) ) has taken place on June 9, 2026.

Globus Medical has seen notable insider activity as Director David Davidar disposed of 25,000 shares of the company’s stock in a transaction valued at $2,019,000. This insider sale may draw attention from investors watching ownership changes among the company’s leadership.

Globus Medical’s stock was influenced by its upbeat Q1 report, which showed strong double‑digit revenue growth, significant margin expansion, and raised EPS guidance driven by operating leverage and Nevro integration synergies. Some analysts adjusted views as they weighed this improving profitability, cash generation, and FDA‑backed product momentum against near‑term risks from Nevro’s revenue softness, higher SG&A, and a shift toward leasing enabling technologies that tempers top‑line visibility.

**Spark’s Take on GMED Stock**

According to Spark, TipRanks’ AI Analyst, GMED is a Outperform.

GMED scores well on fundamentals (strong growth, profitability, cash flow, and a very conservative balance sheet) and the latest earnings update was favorable with raised EPS guidance driven by margin expansion. The main drag is technical weakness (price below key moving averages with negative MACD), with secondary risks from Nevro integration and near-term revenue recognition headwinds in enabling technologies; valuation appears reasonable at ~18x earnings.

To see Spark’s full report on GMED stock,  
 click here. 

**More about Globus Medical**

**YTD Price Performance:** -10.32%

**Average Trading Volume:** 1,409,182

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $10.62B

### Related Stocks

- [GMED.US](https://longbridge.com/en/quote/GMED.US.md)
- [NVRO.US](https://longbridge.com/en/quote/NVRO.US.md)

## Related News & Research

- [Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions | GMED Stock News](https://longbridge.com/en/news/297093370.md)
- [AI agents keep finding ways to bend the rules. Here are some of the wildest.](https://longbridge.com/en/news/298138114.md)
- [An NEA partner says not every AI task needs frontier intelligence](https://longbridge.com/en/news/298434703.md)
- [Anthropic's AI fluency chief says the best AI users know when to do the work themselves](https://longbridge.com/en/news/298433044.md)
- [YieldMax® AI & Tech Portfolio Option Income ETF declares $0.2888 dividend](https://longbridge.com/en/news/298334201.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**